机构地区:[1]河南中医药大学第一附属医院,河南郑州450000
出 处:《中医学报》2023年第7期1566-1571,共6页Acta Chinese Medicine
基 金:河南省中医药科学研究专项课题项目(20-21ZY2188)。
摘 要:目的:观察热敷中药封包联合盐酸坦索罗辛缓释胶囊治疗湿热瘀滞型Ⅲ型前列腺炎的临床疗效。方法:120例Ⅲ型前列腺炎患者为对象,随机分为盐酸坦索罗辛组40例,中药封包组40例,联合组40例。盐酸坦索罗辛组给予盐酸坦索罗辛缓释胶囊,中药封包组给予中药封包热敷,联合组给予中药封包热敷联合盐酸坦索罗辛缓释胶囊,3组均治疗4周。治疗后,比较3组患者临床疗效、慢性前列腺炎症状评分(chronic prostatitis symptom index,NIH-CPSI)、视觉模拟疼痛量表(visual analogu scale,VAS)评分、生活质量(quality of life,QOL)评分、中医证候积分、前列腺液炎症因子[肿瘤坏死因子(tumor necrosis factor-α,TNF-α)、白细胞介素-8(interleuki-8,IL-8)]水平。结果:治疗后,联合组有效率(92.50%)高于中药封包组(70.00%)和盐酸坦索罗辛组(75.00%)(P<0.05)。治疗后,3组患者中医证候评分均低于治疗前,联合组中医证候评分为(9.59±2.17)分,中药封包组为(11.52±2.26)分,盐酸坦索罗辛组为(12.12±2.23)分,联合组低于同期其他两组(P<0.05)。治疗后,3组患者VAS评分、NIH-CPS评分均低于治疗前,联合组VAS评分、NIH-CPS评分分别为(2.15±0.45)、(15.25±3.17)分,中药封包组分别为(4.06±0.94)、(21.46±5.25)分,盐酸坦索罗辛组分别为(4.50±0.61)、(20.46±3.22)分,且联合组以上评分低于其他两组(P<0.05)。治疗后,3组患者QOL评分均高于治疗前,联合组QOL评分为(51.11±4.37)分,中药封包组为(45.27±7.82)分,盐酸坦索罗辛组为(43.66±5.02)分,联合组QOL评分高于其他两组(P<0.05)。治疗后,3组患者TNF-α、IL-8均低于治疗前,联合组TNF-α、IL-8分别为(31.21±5.18)、(2.56±0.54) ng·L^(-1),中药封包组分别为(52.66±8.66)、(5.92±2.25) ng·L^(-1),盐酸坦索罗辛组分别为(55.16±6.20)、(5.18±1.51) ng·L^(-1),且联合组以上指标水平低于其他两组(P<0.05)。结论:热敷中药封包结合盐酸坦索罗辛缓释胶囊治疗湿热�Objective:To observe the clinical efficacy of hot compress traditional Chinese medicine package combined with tamsulosin hydrochloride sustained release capsule in treatment of prostatitisⅢwith Damp-Heat stasis syndrome.Methods:120 prostatitisⅢpatients with were randomly divided into tamsulosin hydrochloride group(n=40),traditional Chinese medicine package group(n=40)and combined group(n=40).Tamsulosin hydrochloride sustained release capsule was given to the tamsulosin hydrochloride group,traditional Chinese medicine package hot compress was given to the traditional Chinese medicine package group,and the combination group was given traditional Chinese medicine package hot compress combined with tamsulosin hydrochloride sustained release capsule.All the three groups were treated for 4 weeks.After treatment,the clinical efficacy,chronic prostatitis symptom index(NIH-CPSI),visual analogu scale(VAS),quality of life(QOL)score,TCM syndrome score,prostatic fluid inflammatory factors(tumor necrosis factor-α[(TNF-α),interleukin-8(IL-8)]were compared among the three groups.Results:(1)after treatment,the effective rate of patients in the combined group(92.50%)was higher than that in the traditional Chinese medicine package group(70.005%)and tamsulosin hydrochloride group(75.00%)(P<0.05).After treatment,the TCM syndrome scores of the three groups were lower than those before treatment.The TCM syndrome scores of the combined group,traditional Chinese medicine package group and tamsulosin hydrochloride group were 9.59±2.17,11.52±2.26 and 12.12±2.23,respectively.The score in the combined group was lower than that in the other two groups in the same period(P<0.05).After treatment,the scores of VAS and NIH-CPS in the three groups were lower than those before treatment.The scores of VAS and NIH-CPS were 2.15±0.45,15.25±3.17 in the combined group,4.064,21.46±5.25 in the traditional Chinese medicine package group,and 4.500.61,20.463.22 in the tamsulosin hydrochloride group(P<0.05).After treatment,the QOL scores of the th
关 键 词:Ⅲ型前列腺炎 热敷中药封包 盐酸坦索罗辛缓释胶囊 湿热瘀滞证
分 类 号:R277.593.3[医药卫生—中医学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...